Bioequivalency Study of Zidovudine Under Fasting Conditions

A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fasting Conditions

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00602550

Enrollment

Registered

2008-01-28

Start date

2003-06-30

Completion date

2003-06-30

Last updated

2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV

Brief summary

The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Interventions

DRUGZidovudine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening.

Exclusion criteria

* Allergic or adverse responses to zidovudine or any other comparable or similar products. * Participation in clinical trial within 30 days of study initiation. * Positive blood screen for HIV, Hepatitis B and C.

Design outcomes

Primary

Measure	Time frame
Bioequivalence	Baseline, Two period, Three day washout

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026